Last reviewed · How we verify
NCT03687931
A Clinical Study to Assess the Efficacy and Safety of Dexamethasone Suspension for Cataract Surgery
Phase 1, PHASE2 trial testing Dexamethasone in Inflammation Eye in 60 participants. Completed in 28 February 2019.
28 February 2019
Quick facts
| Lead sponsor | iDrop, Inc. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 26 August 2018 |
| Primary completion | 28 February 2019 |
| Estimated completion | 28 February 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dexamethasone (dexamethasone) — full drug profile →
Conditions studied
- Inflammation Eye — all drugs for Inflammation Eye →
Sponsor
iDrop, Inc.
Who can join
40 and older, any sex, with Inflammation Eye. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of two dose levels of dexamethasone ophthalmic suspension eye drops to determine if the drops decrease inflammation inside the eye and are safe after cataract surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03687931
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dexamethasone
Trials testing the same drug.
- NCT07543458 — Therapeutics for Moderate and Severe Dengue · Phase 3 · not yet recruiting
- NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Inflammation Eye
Currently open trials in the same condition.
- NCT07262437 — Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles · NA · active not recruiting
Other iDrop, Inc. trials
Trials by the same sponsor.
- NCT04711213 — A Clinical Study to Assess the Efficacy and Safety of SED80 for Use in Cataract Surgery · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03687931 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by iDrop, Inc.
- Last refreshed: 24 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03687931.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing